Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

Weight loss drugs and jabs have become more popular and a recent study looked at the effectiveness of two drugs ...

Although Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, Lilly has gained the lead in obesity ...